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Abstract
Hepcidin a 25-amino-acid and highly disulfide bonded hormone, is the central 
regulator of iron homeostasis. In this chapter we propose ferritin as a peptide 
carrier to promote the association of the hybrid hepcidin/ferritin nanoparticle with 
a particular cell or tissue for therapeutic or diagnostic use. Indeed, human fer-
ritin H-chain fused directly (on its 5’end) with camel mature hepcidin was cloned 
into the pASK-43 plus vector and expressed using BL21 (DE3) pLys E. coli strain. 
The transformed E.coli produced efficiently hepcidin-ferritin construct (hepcH), 
consisting of 213 amino acids with a molecular weight of 24 KDa. The recovered 
product is a ferritin exposing hepcidin on outer surface. The hepcH monomer was 
characterized by immunoblotting using a monoclonal antibody specific for human 
ferritin and a polyclonal antibody specific for hepcidin-25. The results were also 
confirmed by MALDI-TOF mass spectrometry. The recombinant native human fer-
ritin and the commercial human hepcidin-25 were used as controls in this experi-
ment. The assembly of hepcH, as an heteropolymer molecule, was performed in 
presence of denatured human ferritin-H and -L chains. After cysteine oxidation of 
the recombinant nanoparticles, cellular binding assays were performed on mamma-
lian cells such as mouse monocyte–macrophage cell line J774, HepG2 and COS7.
Keywords: camel hepcidin, chimeric nanoparticle, engineered recombinant E. coli, 
human ferritin, protein folding
1. Introduction
The combination of chemistry, biology, and nanotechnology is expected to 
make significant contributions to the field of medical diagnosis and therapeutics. 
In this framework, the use of nanoparticles in vaccine formulations allows not 
only improved antigen stability and immunogenicity, but also targeted delivery 
and slow release. Protein cage architectures such as virus capsids and ferritins are 
versatile nanoscale platforms willing to both genetic and chemical modifications. 
The incorporation of multiple functionalities within these nanometer-sized protein 
architectures reveals their potential to serve as functional nanomaterials with 
applications in medical imaging and therapy. For example, RGD-4C, a cell specific 
targeting peptide, which binds αvβ3 integrins upregulated on tumor vasculature, 
was genetically incorporated on the exterior surface of a human H-chain ferritin 
Tissue Engineering and the 5 R’s - Reconstruction, Restoration, Replacement, Repair...
2
nanoparticle [1]. Interestingly, this modified protein cage binds specifically cancer 
cells in vitro. Thus, the use of ferritin cage architecture is an exciting and promis-
ing strategy to serve as a multifunctional platform for the biomimetic synthesis of 
magnetic nanoparticles. It can be engineered for cell-specific targeting.
Ferritin is probably the most used protein in bio-nanotechnology. This is due to 
its well-known structural features, high stability, capability to mineralize metals 
in its cavity, self-assembly and possibility to redesign its interior and exterior by 
protein engineering. It has been used to encapsulate molecules, for the synthesis of 
inorganic cores, for functional nanostructured composite material, for magnetic 
nanoparticles for MRI applications and for carrying various epitopes. Most pub-
lished studies used the human H or L ferritin chains, which are able to self-assemble 
in different proportions to produce a variety of heteropolymers. This allows the 
possibility to adorn ferritin surface with multiple functionalities through genetic 
and chemical modifications to achieve desired properties for therapeutic and/
or diagnostic purposes. In particular, it can be used as a peptide carrier to target 
specific receptors. Unfortunately, there are no data published concerning functional 
biological peptides genetically fused to ferritin are missing.
In this chapter, we plan to exploit this approach by fusing hepcidin to the ferritin 
molecule. In fact, ferritin and hepcidin are central molecules implicated in the 
regulation of iron homeostasis and the fusion of the two can carry several advan-
tages. For example, the injection of iron-loaded ferritin in a ten days wild mouse 
induces the expression of BMP6 and Hamp1 at dose-dependent manner. Such result 
cannot be obtained through an injection of FAC (ferric ammonium citrate) or 
holo-transferrin. However, the injection of uncharged ferritin has no effect on the 
expression of BMP6 or Hamp1.
We also proposed to use ferritin to carry hepcidin, another key protein of iron 
metabolism. It is a small hormone peptide that control systemic iron homeostasis 
(ferritin is a major controller of cellular iron homeostasis). The production of chi-
meric ferritin complexes that expose on the surface of limited number of functional 
hepcidin is of interest. It is a tool that allows deep studies in relation to the mechanism 
of interaction between hepcidin and ferroportin and how the complex is degraded. 
It might indicate alternative approaches to control hepcidin activity and systemic 
iron homeostasis. Ferritin is composed of 24 subunits. Once defined the conditions 
to insert a novel function and to co-assemble different subunits in a highly stable 
molecule that carries are defined, it is possible to produce molecules with many more 
functions and it can be applied to other peptides and hormones.
The aim of this chapter is to describe an efficient strategy to fuse the full-length 
hepcidin to the N-terminus of ferritin-H chain (which in the assembled protein is 
exposed on the surface). The produced chimeric protein will be tested:
1. As iron regulatory hormone (by studying the hepcidin-ferroportin interac-
tion) which can be useful for patients with iron disorders.
2. As drug-delivery agent.
2. Methods
2.1 Expression and solubilization of HepcH monomer
Human ferritin H-chain fused directly, on its 5’end, with camel mature hepcidin 
was cloned into the pASK-IBA 43 plus vector (Table 1) and expressed using E. coli 
BL21 (DE3) pLysS. Growth of the transformed E. coli was done in 1 L LB medium (10 g 
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Tryptone, 5 g Yeast extract, 5 g NaCl), with100μg/ml AMP, at 37°C, for 1-2 h until 
OD = 0,5. Expression was induced by the addition of 200 μl anhydroteracycline (1 mg/
ml), final concentration 200 μg/L, for 4 h. Cells were harvested by centrifugation at 
7000 RPM for 10 min. The pallet was washed twice in Tris–HCl 20 mM pH 7,4 and 
sonicated, for cytoplasmic protein extraction, at the following conditions: 1 min: 30 sec, 
cycle5, power 72%. The sonicated pallet was centrifuged at 12000 RPM and washed 
twice in Tris 20 mM, 2 M Urea, 0,1% TritonX100, pH 7,4. The insoluble HepcH, precipi-
tating with the inclusion bodies from the E.coli paste, was solubilized with a weight to 
volume ratio of 1:1 in 6 M Guanidine hydrochloride (GdnHCl) pH 4,7. The suspension 
was sonicated at the same conditions to homogenate the solution and incubated with 
stirring, for 18 h at 4°C.
2.2 Assembly and cysteine oxidation of HepcH-FTH heteropolymers
To enhance the assembling of HepcH as an heteropolymer molecule, it was 
mixed, with the molar ratio hepcidin/ferritin of 1:5, in presence of denatured FTH 
in 6 M GdnHCl pH 7. The mixture was then diluted at least 10-fold into 0,1 M 
sodium phosphate pH 7,4, in the presence of 5 mM beta-mercaptoethanol (3 mM 
DTT and 1 mM EDTA), and incubated with stirring for 18 h at 4°C, for the renatur-
ation of the heteropolymer. The diluted solution was then clarified by centrifuga-
tion, at 4000RPM for 15 min, at least twice to separate the soluble fraction from the 
insoluble cellular debris. A 10-fold concentration was performed with a 100-KDa 
molecular weight cutoff membrane. The renatured HepcH-FTH heteropolymer 
was then purified using a gel filtration on a Sepharose 6B column and analyzed 
on native gel 8%. A slightly modified protocol of HepcH-FTH renaturation, using 
different molar ratios of hepcidin/ferritin, was described by Boumaiza et al. [2]. 
Both protocols showed to be efficient for the production of correctly assembled and 
functional HepcH-FTH heteropolymer. Cysteine oxidation for the final refolded 
HepcH-FTH renatured in the proportion hepcidin/ferritin = 1:5, was carried out 
using the glutathione redox system (GSH/GSSG) as described by Jordan et al. [3].
2.3 Cell culture
Mouse monocyte–macrophage cell line J774 (Lombardy and Emilia Romagna 
Experimental Zootechnic Institute) was cultured as previously described by 
Primers Sequence 5′ to 3′ Using
NheI hFTH F CAAATGGCTAGCACGACCGCGTCCA Construction of pASK-
IBA43 plus hFTH vector
BamHI hFTH R TCGAGGGATCCCCGGGTTAGCTTTCATT Construction of pASK-
IBA43 plus hFTH vector
NheI H25 F ATAGACGCTAGCATGGACACCCACTTCCCCATCTGC Construction of pASK-
IBA43 plus HepcD-hFTH 
vector
NheI H25 R ATAGACGCTAGCGGTCTTGCAGCACATCCCAC Construction of pASK-
IBA43 plus HepcD-hFTH 
vector
pASK F GAGTTATTTTACCACTCCCT Sequencing
pASK R CGCAGTAGCGGTAAACG Sequencing
Table 1. 
Sequences of the primes used in this study.
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Delaby et al. [4]. Briefly, cells were grown in DMEM (PAA Laboratories GmbH), 
10% endotoxin-free fetal bovine serum (Euroclone), 0.04 mg/mL gentamicin 
(Euroclone), 2 mM l-glutamine (PAA Laboratories GmbH), and maintained at 37°C 
in 5% CO2. They (200,000 cells/well) were seeded onto 12- well plates, and after 
24 h were grown for 12 h in presence of 100 μM ferric ammonium citrate (FAC) to 
induce ferroportin expression. The day after, cells were incubated with HepcH-FTH 
at final concentrations of 0.5 μM and 0.2 μM. Controls were cells without ferric 
ammonium citrate (FAC) treatment and cells incubated with native FTH homo-
polymer. Experiments were performed at 37°C for 30 min and 2 h. After this time, 
the supernatant was discarded and the cells washed with cold PBS and lysed using 
cold buffer (200 mM Tris–HCl at pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 
10% glycerol, 1 mM sodium fluoride, 1 mM sodium orthovanadate, complete 
protease inhibitor cocktail; Roche). Protein content was determined by colorimetric 
BCA assay (bicinchoninic acid assay, Pierce), 30 μg of total proteins were separated 
by native and denatured polyacrylamide gel electrophoresis and Western blotting, 
for the detection of proteins bound and internalized by the J774 cells, as well as the 
mass spectroscopy analysis were performed as described previously [5].
3. Results and discussion
Ferritin is probably the most used protein in bionanotechnology. This is due to 
its well-known structural features, high stability, capability to mineralize metals 
in its cavity, self-assembly and possibility to redesign its interior and exterior by 
protein engineering [6, 7]. Hepcidin, a 25 amino acid peptide belonging to the 
β-defensins family, was isolated for the first time from plasma and human urine 
respectively by Krause et al. [8] and Park et al. [9]. It is a cysteine-rich cationic 
peptide, engaged with four disulfide bridges, which plays a major role in innate 
immunity and iron homeostasis [10]. It is induced by iron and inflammation and 
is suppressed by iron deficiency and hypoxia. It binds and inhibits ferroportin1, 
the only cellular iron exporter, thus, high hepcidin reduces while low hepcidin 
increases systemic iron availability. This hormone acts via its N-terminal part and 
more precisely the 7–9 amino acids including a single thiol cysteine, comprised the 
minimal structure that retained hepcidin activity [11] and can be refolded in-vitro. 
The 3D structure of human hepcidin is known [3]. Recombinant human and mouse 
hepcidins were expressed in E. coli in fusion with a Thioredoxin and treated by two 
sequential proteolytic enzymes to obtain functional hepcidin, in low yield <10% 
[12]. We used this procedure to clone and express camel hepcidin, in collaboration 
with Prof. Marie-Agnès Sari in the laboratory of Chemistry and Pharmacological 
and Toxicological Biochemistry (UMR 8601) at the University Paris Descartes. 
We showed that this hepcidin is functionally equivalent to human one in bind-
ing and inhibiting ferroportin using mouse monocyte–macrophage cell line J774 
treated with Fe-nitrilotriacetate. Camel hepcidin differs from human hepcidin in 2 
residues, which make it more stable [13]. Thus, we planned to use camel hepcidin 
to make hybrid molecules with ferritin. For this purpose, we have approached the 
laboratory of Prof. Paolo Arosio in Brescia that has a long experience in the produc-
tion of recombinant proteins and is working on ferritin and hepcidin. The aim of 
this work was to fuse the full length hepcidin to the N-terminus of ferritin-H chain, 
which is exposed on the surface in the assembled protein. The chimeric subunit was 
assembled in the 24-mer shells together with various proportion of H or L chains to 
produce hybrid heteropolymers. These latter that can carry 1 to 24 hepcidin moi-
eties and other functions that can be engineered and can include the electron dense 
iron core as tracer.
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We cloned the gene encoding camel hepcidin in fusion with the 5′ of the cDNA 
for heavy chain of human ferritin into the pASK-IBA 43plus vector (Figure 1A, B) 
for high expression in E. coli. The clone was verified and expressed the chimeric 
peptide in high amount but it was insoluble and could not be easily refolded in a 
soluble and active 24-mer shell. Thus, we planned to carry out this project with 
different strategies:
The construct was expressed in the prokaryotic system E.coli BL21 (DE3) pLysS, 
and the peptides were initially characterized on polyacrylamide gel in denatur-
ing conditions (Figure 2A), western blotting (Figure 2B) and MALDI-TOF mass 
spectrometry. Hepcidin carries 8 cysteines that form 4 disulfide bridges in the 
folded molecule, while FTH has three cysteines, which do not form bonds. Thus, 
the presence of free -SH groups was also quantified throughout all the purification 
and refolding processes. We planned to produce bicistronic constructs that express 
the chimeric hepcidin-FTH and the FTH-WT, with an approach that has been found 
successful for the production of insoluble ferritin mutants [14]. We obtained fer-
ritin shells with low proportion of chimeric hepcidin (Figure 1C, D). In parallel, we 
have performed co-renaturation together with ferritin-H or L chains. We obtained 
molecules with various amounts of hepcidin. To this aim the in-vitro refolding of 
the fusion protein hepcH was done with different molar ratio of H and L chains, 
in order to optimize the assembly of the hybrid nanoparticles [2]. Purified fusion 
hepcidin–ferritin H subunit (Figure 3D) assembled together with H- or L-chains 
at a ratio of 1:5, produced a stable and functional 24-mer ferritin exposing about 
4 hepcidin per shell (Figure 1C, D; Figure 3C). HepcH-FTH heteropolymer was 
purified and characterized by analysis on polyacrylamide gel in non-denaturing 
condition and by western blotting (Figure 3E, F, G, H). MALDI-TOF spectra of 
the final oxidized HepcH-FTH heteropolymer exhibited, average mass peaks at m/z 
21135.97 and at 243775.51 (Figure 4A) which corresponds to the theoretical average 
mass [M + H] + of 21225.64 of FTH (183 amino acids), and of 24410.50 to HepcH 
(213 amino acids).
These procedures have produced ferritin shells that expose on the surface 
the hepcidin moiety. In order to control the correct folding, the cysteines of the 
Figure 1. 
(A) Construction of the recombinant HepcH pASK-IBA 43 plus vector. (B) Amino acid sequence of the fusion 
HepcH protein. In this recombinant protein, the coding sequence of camel hepcidin, in red and italic, was fused 
directly to the 5′ end of human H-ferritin, in green, and cloned into pASK-IBA43 plus vector. (C) Schematic 
representation (left) and space-filling diagram (right) of the assembled HepcH-FTH heteropolymer (with 
molar ratio hepcidin/ferritin = 1:5).
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molecule was reduced and then slowly oxidized under controlled conditions (to 
allow the formation of the correct four disulfide bridges constituting the hormone). 
In case the cysteine of the ferritin interferes with the process or its monitoring by 
spectroscopic techniques, they could be removed by site-directed mutagenesis.
The functionality of the assembled heteropolymer was analyzed by its capacity 
to bind with high affinity the ferroportin, which is the natural hepcidin receptor. 
To this goal, we used the macrophagic cell line J774 that expose evident ferroportin 
after treatment with iron. The cells were incubated with the hybrid molecules and the 
binding analyzed directly with traced anti-ferritin antibodies. Binding specificity was 
analyzed by adding ferritin and synthetic hepcidin. This process was repeated with the 
various heteropolymer types. Next, we studied the biological activity of the chimera, 
Figure 2. 
(A) SDS-PAGE analysis of the induced and uninduced E.coli transformed by the recombinant HepcH-FTH 
pASK-IBA 43 plus vector. Lane 1 and 2, induced and uninduced pellet respectively (insoluble fraction). 
Lane 3 and 4, induced and uninduced supernatant (soluble fraction). Lane 5 and 6, induced and uninduced 
total sonicate (total protein). (B) Western blot analysis of the recombinant HepcH monomer (in denaturing 
conditions). Lane 1, rabbit hepcidin antibodies recognized the human hepcidin-25 (control). Lane2, rabbit 
hepcidin antibodies recognized the recombinant HepcH. Lane3, rH02 antibodies recognized the recombinant 
HepcH. Lane4, rH02 antibodies recognized the recombinant human H-ferritin (control).
Figure 3. 
Renaturation of the insoluble HepcH monomer in absence and in presence of FTH. (A) Purified FTH (line1) 
and solubilized HepcH monomer (line 2 and 3) analyzed on denaturing conditions. (B) FTH homopolymer 
(line1) and renatured HepcH, in absence of FTH, analyzed on non-denaturing conditions (line 2 and 3). 
(C) FTH homopolymer (line1) and renatured HepcH in presence of FTH with molar ratio of hepcidin/
ferritin = 1:5 (lane 2 and 3) analyzed on non-denaturing conditions. (D) SDS-PAGE analysis of the purified 
HepcH, from the insoluble fraction (IS), by gel filtration on a Sepharose 6B column (GE Healthcare, life 
sciences). (E) Fast protein liquid chromatography chromatogram showing the purification of HepcH-FTH 
heteropolymer using a gel filtration on a Sepharose 6B column and analyzer on non-denaturing conditions (F). 
(G) Western blot analysis of the purified HepcH-FTH heteropolymer using the anti-rabbit hepcidine-25 and 
the human ferritin-H antibodies, rH02, as control (H).
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in particularly if it is taken up and degraded together with ferroportin, as it occurs with 
the hepcidin. Hybrid and native ferritin binding to murine J774 cells were monitored 
using monoclonal anti-human FTH antibody rH02 that does not cross-react with the 
mouse ferritins [15]. This was confirmed by treating J774 cells with mouse ferritin 
alone or together with HepcH-FTH. The obtained results (Figure 5A) showed that 
these antibodies are specific only to human H-ferritin. J774 cells treated with 100 μM 
FAC showed to be able to internalize HepcH-FTH heteropolymers after 30 min to 2 h of 
incubation at 37°C (Figure 5B). Hepcidin exerts it function by binding and then induc-
ing ferroportin degradation, and in fact we observed that after 2 h incubation, with a 
final concentration of 0.2 μM, more efficiently than human hepcidin-25 used as control 
Figure 4. 
(A) High-resolution MALDI-TOF/TOF mass analysis of the recombinant assembled HepcH-FTH 
heteropolymer and the recombinant human ferritin FTH homopolymer (B).
Figure 5. 
(A) Western blot analysis of the J774 cells treated with mouse ferritin (Mo-Ft), FTH, human hepcidin-25 and 
HepcH-FTH heteropolymer using anti-FTH antibodies (rH02). Lane 1, cells treatment with 0.5 μM Mo-Ft 
and HepcH-FTH; lane 2, cells treatment with 0.5 μM FTH; lane 3, cells treatment with 0.5 μM Mo-Ft; lane 4, 
untreated cells. (B) Western blot analysis of the J774 cells treated with 0.5 μM HepcH-FTH heteropolymer and 
FTH, using anti-FTH antibodies (rH02). Lane 1, non-treated cells; lane2, cells treated with 6 M guanidine; 
lane 3, cells treated with 0.5 μM FTH for 30′; lane 4, cells treated with 0.5 μM HepcH-FTH for 30′; lane 5, 
cells treated with human hepcidin for 30 min; lane 6, cells treated with FTH for 2 h; lane 7, cells treated with 
HepcH-FTH for 2 h; lane 8, cells treated with human hepcidin for 2 h. (C) Western blotting analysis of the 
SDS-PAGE of cell lysates using polyclonal anti-rabbit ferroportin antibody. CTR: Untreated cells. FTH: Cells 
treatment with 0.5 μM native FTH for 2 h. HepcH-FTH: Cells treatment with 0.2 μM HepcH-FTH (with 
molar ration of 1:5) for 2 h. Hepc: Cells treatment with 0.5 μM synthetic human hepcidin-25 for 2 h. non-
adjacent bands, from the same blot, were denoted by vertical black lines.
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(Figure 5C). Indeed, the level of ferroportin in the J774 cells decreased, as it occurred in 
the cells treated with the synthetic hepcidin, while the incubation with FTH had no evi-
dent effect. This indicates that heteropolymer is biologically functional. Consequently, 
folded camel hepcidin activity against FPN1 could be enhanced thanks to its exposition, 
through its N-terminal part, at the H-ferritin surface nanocage [16]. This will probably 
offer a tool for a detailed study of the events after ferroportin binding the hepcidin. The 
heavy ferritin iron core and the fate of iron will facilitate the monitoring of the process.
As perspectives, the examination of the chronic effect of the purified hetero-
polymer injections on liver iron accumulation in a mouse model of hereditary 
hemochromatosis could be monitored. Indeed, hepcidin-1 knockout mice 
(hepc1−/−) can be used, as a model, to eliminate any possibility of endogenous 
hepcidin contributing to the regulation of iron loading. This strategy can also be 
developed by producing ferritin subunits carrying other functionalities or epitopes, 
in order to have multifunctional complexes. Moreover, involving the approach can 
be applied for other peptides/hormones for the design of ‘smart’ molecular systems 
programmed to allow the transport in the body of potent anticancer agents in an 
innocuous manner toward safe tissues. Thus, these hybrid molecules will be use-
ful for future therapeutic applications to improve health and life quality of a great 
number of patients with iron disorders or cancer diseases.
4. Conclusion
Ferritin is a well-known molecule with enormous potentiality in biotechnology. 
It has been already used to encapsulate molecules, as contrast in MRI and to carry 
epitopes. This chapter offers an original strategy to design a new bifunctional hybrid 
protein, which can be proposed as a stable iron regulatory molecule or a drug-delivery 
agent. The results could be exploited by scientists to produce ferritin subunits carry-
ing other functionalities or epitopes, in order to have multifunctional complexes. It 
can be a new platform with utmost importance in the field of cell and gene therapies.
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